Indivior (INDV)


INDV Share PerformanceMore

52 week high382.30 17/02/17
52 week low136.00 03/05/16
52 week change 166.60 (98.93%)
4 week volume43,079,519 02/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Indivior schedules Q1 results announcement

Indivior has confirmed that the Company will report its financial results for Q1 2017 on 3 May. At 2:03pm: (LON:INDV) In...

Notice of Results

RNS Number: 5866C Indivior PLC 19 April 2017 Indivior PLC (the 'Company') Notification of First Quarter Results The Company is due to report its financial results for Q1 2017 on May 3 rd , 2017. The results will be released via Regulatory News Service, and shortly thereafter on the Company website, at 1200hrs GMT UK (0700hrs EDT in the USA). There will be a co...

Holding(s) in Company

RNS Number: 9183B Indivior PLC 07 April 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Indivior PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or dispos...

Additional RBP-6000 Clinical Study Results

RNS Number: 7411A Indivior PLC 28 March 2017 Indivior Announces Additional Results from Clinical Studies Further Supporting the Relationship Between Sustained Plasma Levels of Buprenorphine as Delivered by RBP-6000 Monthly Depot, High Levels of -Opioid Receptor Occupancy in the Brain, and Clinical Efficacy Results also include preliminary health econ...

Indivior sets date for AGM

Indivior has confirmed that the Annual General Meeting of the Company is scheduled to be held at 3.00pm on Wednesday...

Annual Financial Report

RNS Number: 3055A Indivior PLC 23 March 2017 Indivior PLC ('Indivior' or the 'Company') Annual Report and Accounts for the year ended December 31, 2016 ('Annual Report & Accounts 2016') and Annual General Meeting 2017 ('AGM') The Company has today posted or made available to shareholders the following documents: Annual Report & Accounts 2016; Not...

Top-line Phase 3 Trial Results - RBP-7000

RNS Number: 2769Z Indivior PLC 13 March 2017 Indivior PLC Announces Positive Top-line 12-Month Phase 3 Results Confirming Long-Term Safety Profile of RBP-7000 in Patients with Schizophrenia Results represent the first demonstration of safety and durability of effect for a once-monthly injectable form of subcutaneously-administered risperidone in a long-t...

Broker Forecast - RBC Capital Markets issues a broker note on Indivior Plc

RBC Capital Markets today downgrades its investment rating on Indivior Plc (LON:INDV) to sector performer (from outp...

Latest discussion posts More

  • Takeover?

    The FT quotes: "If Indivior can navigate these legal risks while keeping market share steady, ?it could become a target for a larger peer,? RBC said in a recent note. RBC named ...
  • NEW ARTICLE: Don't write off reliable Reckitt Benckiser

    "With the fatal South Korean disinfectant scandal, tough Russian market and sluggish take-up of Scholl footwear products, LSE:RB.:Reckitt Benckiser missed City forecasts in the ...
    II Editor
  • Re: Time to bank profits?

    The Telegraph's Questor again showed his form in advising to sell these at #1.70 a couple of months ago, and now they are #3.42. The RB-6000 drug had good results in its ...

Users' HoldingsMore

Users who hold Indivior also hold..
RDS 'B'31%

Codes & Symbols